Related Experiment Video
Updated: Aug 10, 2026

12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
Human anti-self antibodies with high specificity from phage display libraries
A D Griffiths1, M Malmqvist, J D Marks
1MRC Centre for Protein Engineering, Cambridge, UK.
The EMBO Journal
|February 1, 1993
Summary
Researchers isolated human antibody fragments that bind to self-antigens from unimmunized donors. These antibody fragments, derived from peripheral blood lymphocytes (PBLs), show high specificity and can be engineered for therapeutic applications.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Human antibody fragments binding foreign antigens can be isolated from peripheral blood lymphocytes (PBLs).
- V-genes from PBL mRNA can be shuffled and displayed as single-chain Fv (scFv) fragments on phage for antigen selection.
Purpose of the Study:
- To investigate the isolation of scFv fragments binding human self-antigens from a phage library.
- To characterize the binding kinetics and potential therapeutic applications of these self-antigen-binding scFv fragments.
Main Methods:
- Phage display library construction using shuffled heavy and light chain V-genes from unimmunized human PBLs.
- Selection of scFv fragments by phage binding to human self-antigens.
- Analysis of scFv fragment composition (monomers/dimers) using FPLC gel filtration.
- Determination of binding kinetics (association, dissociation, affinity) using surface plasmon resonance.
Main Results:
- Isolation of scFv fragments with high specificity for human self-antigens from the phage library.
- Identification of both unmutated and mutated V-genes encoding these self-reactive scFv fragments.
- Characterization of scFv dimer binding kinetics: association (k(on) = 10^5-10^6 M^-1s^-1), dissociation (k(off) = 10^-2 s^-1), and affinity (Ka = 10^7 M^-1).
- Observed relatively fast dissociation kinetics for the scFv dimers.
Conclusions:
- Phage libraries derived from human PBLs can yield scFv fragments with high specificity for self-antigens.
- The binding kinetics, particularly dissociation rates, suggest potential for in vitro affinity maturation for therapeutic purposes.
- Engineered antibody fragments could offer novel therapeutic strategies targeting self-antigens.
More Related Videos
Related Concept Videos
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

